Wells Fargo’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,519
| Closed | -$84K | – | 7932 |
|
|
2022
Q2 | $84K | Buy |
1,519
+319
| +27% | +$16.7K | ﹤0.01% | 4743 |
|
|
2022
Q1 | $38K | Hold |
1,200
| – | – | ﹤0.01% | 5781 |
|
|
2021
Q4 | $26K | Hold |
1,200
| – | – | ﹤0.01% | 6251 |
|
|
2021
Q3 | $26K | Hold |
1,200
| – | – | ﹤0.01% | 5887 |
|
|
2021
Q2 | $23K | Buy |
1,200
+1,000
| +500% | +$18.2K | ﹤0.01% | 5850 |
|
|
2021
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 6608 |
|
|
2020
Q4 | $3K | Hold |
200
| – | – | ﹤0.01% | 6252 |
|
|
2020
Q3 | $2K | Hold |
200
| – | – | ﹤0.01% | 6164 |
|
|
2020
Q2 | $2K | Hold |
200
| – | – | ﹤0.01% | 6131 |
|
|
2020
Q1 | $2K | Sell |
200
-177
| -47% | -$2.32K | ﹤0.01% | 6033 |
|
|
2019
Q4 | $5K | Sell |
377
-6
| -2% | -$78 | ﹤0.01% | 6058 |
|
|
2019
Q3 | $6K | Buy |
383
+1
| +0.3% | +$19 | ﹤0.01% | 6040 |
|
|
2019
Q2 | $8K | Hold |
382
| – | – | ﹤0.01% | 5968 |
|
|
2019
Q1 | $27K | Hold |
382
| – | – | ﹤0.01% | 5456 |
|
|
2018
Q4 | $20K | Sell |
382
-291
| -43% | -$18.6K | ﹤0.01% | 5783 |
|
|
2018
Q3 | $45K | Sell |
673
-40
| -6% | -$3.63K | ﹤0.01% | 5625 |
|
|
2018
Q2 | $85K | Hold |
713
| – | – | ﹤0.01% | 5443 |
|
|
2018
Q1 | $59K | Buy |
713
+155
| +28% | +$17.6K | ﹤0.01% | 5515 |
|
|
2017
Q4 | $83K | Buy |
558
+329
| +144% | +$31.6K | ﹤0.01% | 5376 |
|
|
2017
Q3 | $14K | Hold |
229
| – | – | ﹤0.01% | 5803 |
|
|
2017
Q2 | $11K | Hold |
229
| – | – | ﹤0.01% | 5766 |
|
|
2017
Q1 | $14K | Hold |
229
| – | – | ﹤0.01% | 5795 |
|
|
2016
Q4 | $14K | Buy |
+229
| New | +$14.3K | ﹤0.01% | 5719 |
|
Other funds holding SRRA
Wells Fargo's SRRA Position: Q3 2022 in Review
Wells Fargo sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,519 shares — an estimated $84K sold.
Wells Fargo first reported a position in SRRA in Q4 2016 and held it in 23 quarters. The position peaked at $85K in Q2 2018. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Wells Fargo reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Wells Fargo sold 1,519 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $84K.
- Wells Fargo first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2016 and held it in 23 quarters.
- Wells Fargo's Sierra Oncology, Inc. Common Stock position peaked at $85K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Wells Fargo's 13F filing for Q3 2022, filed 14 Nov 2022.